EUCTR2013-003628-35-IT进行中（未招募）不适用
A COMBINATION THERAPY COMPRISING A 'MEGADOSE' OF T CELL DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANT POST-TRANSPLANT CYCLOPHOPHAMIDE AND A REDUCED INTENSITY CONDITIONING FOR A STABLE AND LONG TERM ENGRAFTMENT - T CELL DEPLETED HSCT, REDUCED INTENSITY CONDITIONING AND POST-TRANSPLANT CYCLOPHOPHAMIDE
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- age between 18 and 70; - Diagnosis according to the WHO classification: CLL patients with refractoriness to fludarabine or other chemotherapy due to the p53 loss by 17p deletion and/or TP53 mutation; Follicular lymphoma with either unfavourable cytogenetics such as complex karyotype, del17p, del 6q23-26, mutations in TP53, minus 1p; Hodgkin's Lymphoma relapsed after autologous transplantation, not elegible for immunotherapy with anti-CD30- Multiple myeloma relapsing after autologous transplantation, with unfavourable cytogenetics in either partial or complete remission. Non available
- •matched unrelated donor.Availability of haploidentical family donor; patients has an Eastern Cooperative Oncology Group (ECOG) performance status = 2; understands and voluntarily signs an informed consent form, skilled in adhering to the study visit schedule and other protocol requirements; creatinine clearance <1,5 or GFR >30 ml/min-
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 9
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •- age <18 and >70; - creatinine clearance >1,5 or GFR <30 ml/min ; -
- •cardiac ejection fraction <40%; - presence of second malignancies ; -
- •Patient has a known history of HIV seropositivity; - Patient has active
- •HBV hepatitis. The following categories of HBV positive patients but with
- •non evidence of active hepatitis may be considered for the study:
- •HBsAg+ and HBV DNA <2000 UI/mL (inactive carriers);HBV DNA >2000
- •UI/mL is criteria of exclusion, Patient is HBsAg- HBsAb+ Patient is
- •HBsAg- HBcAb+ Patients with HCV active hepatitis are excluded from the
- •study, Psychiatric problems, Inability to provide informed consent
研究者
相似试验
进行中（未招募）
1 期
Demonstration of equivalent effectiveness of a novel anti-allergic nasal spray and a marketed nasal product as well as demonstration of fast symptom reduction in allergic patients.Allergic Rhinitis/ RhinoconjunctivitisMedDRA version: 20.0Level: PTClassification code 10039085Term: Rhinitis allergicSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10019170Term: Hay feverSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10048908Term: Seasonal allergySystem Organ Class: 10021428 - Immune system disordersEUCTR2018-001324-19-ATMarinomed Biotech AG84
招募中
不适用
Triple therapy convenience by the use of one or multiple inhaler and digital support in Chronic Obstructive Pulmonary DiseaseChronic obstructive pulmonary disease (COPD)10038716NL-OMON51328Franciscus Gasthuis & Vlietland300
已完成
不适用
A combination treatment of Well-being Therapy and Trauma-Focused Therapy for patients with PTSDNL-OMON48682Mediant (Enschede)38
已完成
不适用
Development of a comprehensive treatment based on psychosocial approach for support for the individuals with early psychosisPsychotic disorders A nurse working in a Psychiatric hospitalJPRN-UMIN000031268Tohoku University20
尚未招募
2 期
The therapeutic effect of the combination of altplas and ibtifibatide (integrilin) in comparison with altplas (r-TPA) alone, in the treatment of acute ischemic strokeAcute Ischemic Stroke.Cerebellar stroke syndromeG46.4IRCT20170117032025N9Hamedan University of Medical Sciences50